Gw615311X

Gw615311X

SCHEMBL30467439

O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 18/20 1.00
▸ ERBB2 P04626 14/20 1.00
▸ ABL1 P00519 2/20 0.70
▸ INSR P06213 2/20 0.70
▸ PDGFRB P09619 2/20 0.70
▸ CDK2 P24941 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ PIK3C2B O00750 1/20 0.70
▸ MAP2K7 O14733 1/20 0.70
▸ RIPK2 O43353 1/20 0.70
▸ PIK3C2G O75747 1/20 0.70
▸ STK10 O94804 1/20 0.70
▸ ABCB11 O95342 1/20 0.70
▸ RET P07949 1/20 0.70
▸ CYP3A4 P08684 1/20 0.70
▸ SRC P12931 1/20 0.70
▸ CYP3A5 P20815 1/20 0.70
▸ ERBB3 P21860 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ KCNH2 Q12809 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw615311X SCHEMBL4006420 1.00 EGFR (1.00) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL4006411 0.91 EGFR (1.00) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL14572854 0.90 EGFR (1.00) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL4003647 0.89 EGFR (0.84) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL13900564 0.88 EGFR (0.87) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL20305523 0.86 EGFR (0.77) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL8213535 0.86 EGFR (0.78) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL4003281 0.85 EGFR (0.75) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL12200053 0.85 EGFR (0.82) EGFRERBB2ABL1INSRPDGFRB
SCHEMBL10118654 0.85 EGFR (0.78) EGFRERBB2ABL1INSRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES GERO PTE LTD (SG) 2023-06-22 — — US claimed
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES GERO PTE LTD (SG) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES AGER, CKMT1A; CKMT1B, GLA EGFR 1153/4885ERBB2 1599/4885ABL1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback